Amy Zhang, M.S.

Amy brings over a decade of experience in the biotech and medical device industries, driving strategy and execution across discovery, regulatory submissions, and clinical development. She has led cross-functional teams in advancing cell therapy, combination products, and biologics. Most recently, at Abbott Laboratories, Amy supported global regulatory compliance for vascular devices, translating clinical evidence into regulatory submissions and responses. Prior to Abbott, she managed early-stage programs at biotech startups including Viridian Therapeutics and Sigilon Therapeutics, advancing monoclonal antibody and cell therapy assets for rare and autoimmune diseases. Amy holds a Master’s in Medical Sciences from Boston University and a Bachelor’s in Biology from Indiana University.